alexa
Reach Us +1-504-608-239
Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer | OMICS International | Abstract
ISSN: 2577-0535

Journal of Cancer Clinical Trials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer

Jennifer Anderson* and Sandra Cuellar

University of Illinois at Chicago College of Pharmacy, 833 S Wood St., Chicago, IL 60612, USA

*Corresponding Author:
Jennifer Anderson
University of Illinois at Chicago College of Pharmacy
833 S Wood St., Chicago, IL 60612, USA
Tel: 312-996-1366
E-mail: [email protected]

Received date: March 02, 2016; Accepted date: April 05, 2016; Published date: April 12, 2016

Citation: Anderson J, Cuellar S (2016) Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer. J Cancer Clin Trials 1:112. doi:10.4172/jcct.1000112

Copyright: © 2016 Anderson J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The inhibitors of mammalian target or rapamycin (mTOR) exhibit antitumor activity via disruption of various signaling pathways and have shown activity when used in combination with hormonal therapy in breast cancer. A review of the role of the efficacy and management of adverse effects of everolimus in combination with exemestane in advanced breast cancer was previously reported by Ng and colleagues. The purpose of this commentary is to provide an update on the efficacy and safety of everolimus in advanced breast cancer, as well as explore the prognostic role of biomarkers. Since 2012, there has been an update on the efficacy of BOLERO-2 as well as an examination of biomarkers. Additionally, everolimus has been investigated in other settings for advanced breast cancer. An update on the adverse effect profile and management of stomatitis associated with everolimus is also provided.

Top